MYDA Advisors LLC purchased a new stake in GlycoMimetics Inc (NASDAQ:GLYC) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 15,000 shares of the biotechnology company’s stock, valued at approximately $252,000.
Several other institutional investors have also bought and sold shares of GLYC. SG Americas Securities LLC purchased a new stake in shares of GlycoMimetics in the fourth quarter valued at approximately $103,000. Fox Run Management L.L.C. purchased a new stake in shares of GlycoMimetics in the third quarter valued at approximately $173,000. First Mercantile Trust Co. boosted its stake in shares of GlycoMimetics by 26.6% in the fourth quarter. First Mercantile Trust Co. now owns 11,726 shares of the biotechnology company’s stock valued at $197,000 after buying an additional 2,466 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of GlycoMimetics in the fourth quarter valued at approximately $210,000. Finally, Dynamic Technology Lab Private Ltd boosted its stake in shares of GlycoMimetics by 43.7% in the third quarter. Dynamic Technology Lab Private Ltd now owns 18,974 shares of the biotechnology company’s stock valued at $265,000 after buying an additional 5,767 shares in the last quarter. Hedge funds and other institutional investors own 92.90% of the company’s stock.
A number of research firms recently weighed in on GLYC. BidaskClub downgraded GlycoMimetics from a “buy” rating to a “hold” rating in a research note on Thursday, March 8th. Roth Capital set a $35.00 price target on GlycoMimetics and gave the company a “buy” rating in a research note on Thursday, February 8th. Zacks Investment Research downgraded GlycoMimetics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 17th. Jefferies Group reiterated a “buy” rating and set a $21.00 target price on shares of GlycoMimetics in a research report on Wednesday, December 20th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $23.00 target price on shares of GlycoMimetics in a research report on Thursday, December 14th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company’s stock. GlycoMimetics has a consensus rating of “Buy” and an average target price of $23.00.
GlycoMimetics (NASDAQ:GLYC) last posted its earnings results on Tuesday, March 6th. The biotechnology company reported ($0.27) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.26) by ($0.01). research analysts predict that GlycoMimetics Inc will post -1.01 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This piece was originally published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://stocknewstimes.com/2018/03/14/myda-advisors-llc-takes-252000-position-in-glycomimetics-inc-glyc.html.
GlycoMimetics Company Profile
GlycoMimetics, Inc is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease.
Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.